Biological Fingerprint Identifies Leiomyomatosis and Renal Cell Cancer
By LabMedica International staff writers Posted on 31 May 2011 |
A diagnostic test involves screening tumor samples for a particular molecular fingerprint unique to leiomyomatosis and renal cell cancer (HLRCC).
A protein modification induced by FH deficiency (due to an over-abundance of fumarate) was identified by scientists at the Henry Wellcome Building for Molecular Physiology, University of Oxford (United Kingdom). This alteration is unique to HLRCC and can be used as a biomarker–a biological 'fingerprint' to identify tumors caused by this mechanism.
The disorder is caused by mutations, which may be inherited, in a gene responsible for the production of an enzyme known as fumarate hydratase (FH). This leads to an accumulation within cells of fumarate, which promotes the development of cancer cells.
Screening cases of papillary renal cell cancer using the new test allows scientists to identify undiagnosed cases of HLRCC for genetic testing. The team that developed the test believes that it should be applied to all cases of papillary renal cell cancer to identify those with FH mutations, allowing advice to be provided to their families on their own relative risks of developing the disorder and associated kidney cancer.
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder which causes the development of benign but often painful tumors in the skin and, in females, in the uterus. Between one in six and one in ten people affected by the disorder will go on to develop an aggressive form of kidney cancer called papillary renal cell cancer. The condition often strikes people in their twenties.
Dr. Lesley Walker, director of cancer information at Cancer Research UK (London, United Kingdom), said: "Tests like this can also help us to identify other patients with the same mutation, paving the way for the development of targeted treatments for specific groups of patients. This approach is called stratified medicine and many scientists now believe it could revolutionize cancer treatment in the future."
Related Links:
Cancer Research UK
Henry Wellcome Building for Molecular Physiology, University of Oxford
A protein modification induced by FH deficiency (due to an over-abundance of fumarate) was identified by scientists at the Henry Wellcome Building for Molecular Physiology, University of Oxford (United Kingdom). This alteration is unique to HLRCC and can be used as a biomarker–a biological 'fingerprint' to identify tumors caused by this mechanism.
The disorder is caused by mutations, which may be inherited, in a gene responsible for the production of an enzyme known as fumarate hydratase (FH). This leads to an accumulation within cells of fumarate, which promotes the development of cancer cells.
Screening cases of papillary renal cell cancer using the new test allows scientists to identify undiagnosed cases of HLRCC for genetic testing. The team that developed the test believes that it should be applied to all cases of papillary renal cell cancer to identify those with FH mutations, allowing advice to be provided to their families on their own relative risks of developing the disorder and associated kidney cancer.
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder which causes the development of benign but often painful tumors in the skin and, in females, in the uterus. Between one in six and one in ten people affected by the disorder will go on to develop an aggressive form of kidney cancer called papillary renal cell cancer. The condition often strikes people in their twenties.
Dr. Lesley Walker, director of cancer information at Cancer Research UK (London, United Kingdom), said: "Tests like this can also help us to identify other patients with the same mutation, paving the way for the development of targeted treatments for specific groups of patients. This approach is called stratified medicine and many scientists now believe it could revolutionize cancer treatment in the future."
Related Links:
Cancer Research UK
Henry Wellcome Building for Molecular Physiology, University of Oxford
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans